Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
9
WINT Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
-11.7%
Day range:
$0.0097 - $0.0114
52-week range:
$0.0078 - $4.2900
Dividend yield:
0%
P/E ratio:
0.00x
P/S ratio:
0.26x
P/B ratio:
0.41x
Volume:
129.6K
Avg. volume:
385.7K
1-year change:
-99.69%
Market cap:
$357.3K
Revenue:
--
EPS (TTM):
-$8.51
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Windtree Therapeutics, Inc. has 37635.85% upside to fair value with a price target of $4.0000 per share.
WINT vs. S&P 500
-
Over the past 5 trading days, Windtree Therapeutics, Inc. has underperformed the S&P 500 by -11.66% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Windtree Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Windtree Therapeutics, Inc. revenues have been falling on a year-over-year basis for 6 quarters in a row. In the most recent quarter Windtree Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Windtree Therapeutics, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Windtree Therapeutics, Inc. reported earnings per share of -$1.08.
Enterprise value:
13.1M
EV / Invested capital:
--
Price / LTM sales:
0.26x
EV / EBIT:
--
EV / Revenue:
1.88x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.87x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$412K
Return On Assets:
-150.5%
Net Income Margin (TTM):
--
Return On Equity:
-760.4%
Return On Invested Capital:
-320.18%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$408K | -$194K | -$412K | -$127K | -$360K | |
| Operating Income | -$15.6M | -$25.6M | -$16.2M | -$4.7M | -$3.8M | |
| EBITDA | -$15.2M | -$25.4M | -$15.8M | -$4.6M | -$3.4M | |
| Diluted EPS | -$17,830.94 | -$931.66 | -$8.51 | -$211.39 | -$1.08 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $26.4M | $10M | $8.9M | $3.9M | $7.2M | |
| Total Assets | $84.8M | $48.1M | $36.1M | $30.4M | $16M | |
| Current Liabilities | $5.1M | $4M | $3.7M | $14.4M | $21.9M | |
| Total Liabilities | $34.6M | $30.7M | $28.6M | $23.9M | $27.6M | |
| Total Equity | $50.2M | $17.4M | $7.5M | $6.6M | -$11.6M | |
| Total Debt | $17.2M | $16.7M | $16.3M | $784K | $240K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$13.3M | -$15.3M | -$15.1M | -$6.4M | -$6.4M | |
| Cash From Investing | -$15K | -$12K | -$6M | -- | -$789K | |
| Cash From Financing | $12.2M | $10.1M | $19M | $6.9M | $7.1M | |
| Free Cash Flow | -$13.3M | -$15.3M | -$15.1M | -$6.4M | -$6.4M | |
WINT
Sector
Market Cap
$357.3K
$25.8M
Price % of 52-Week High
0.25%
50.24%
Dividend Yield
0%
0%
Shareholder Yield
-1234.93%
-1.64%
1-Year Price Total Return
-99.7%
-18.88%
Beta (5-Year)
0.663
0.496
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
5.09%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0112
200-day SMA
Sell
Level
$0.2837
Bollinger Bands (100)
Sell
Level
0.0142 - 0.0942
Chaikin Money Flow
Sell
Level
-613.4K
20-day SMA
Sell
Level
$0.0115
Relative Strength Index (RSI14)
Sell
Level
35.0707
ADX Line
Sell
Level
26.8958
Williams %R
Neutral
Level
-73.8318
50-day SMA
Sell
Level
$0.0223
MACD (12, 26)
Buy
Level
0.0030
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
266.1K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-45.3049)
Sell
CA Score
(Annual)
Level (-5.2417)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (8.3617)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (0)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. It's portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.
Stock Forecast FAQ
In the current month, WINT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The WINT average analyst price target in the past 3 months is $4.0000.
-
Where Will Windtree Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Windtree Therapeutics, Inc. share price will rise to $4.0000 per share over the next 12 months.
-
What Do Analysts Say About Windtree Therapeutics, Inc.?
Analysts are divided on their view about Windtree Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Windtree Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $4.0000.
-
What Is Windtree Therapeutics, Inc.'s Price Target?
The price target for Windtree Therapeutics, Inc. over the next 1-year time period is forecast to be $4.0000 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is WINT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Windtree Therapeutics, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of WINT?
You can purchase shares of Windtree Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Windtree Therapeutics, Inc. shares.
-
What Is The Windtree Therapeutics, Inc. Share Price Today?
Windtree Therapeutics, Inc. was last trading at $0.0100 per share. This represents the most recent stock quote for Windtree Therapeutics, Inc.. Yesterday, Windtree Therapeutics, Inc. closed at $0.0106 per share.
-
How To Buy Windtree Therapeutics, Inc. Stock Online?
In order to purchase Windtree Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get WINT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
WINT
Sector
P/E ratio
0.00x
23.44x
PEG ratio
--
-0.01x
P/B ratio
0.41x
1.81x
Price / LTM sales
0.26x
1.56x
Growth Metrics
WINT
Sector
Revenue growth
--
3.27%
Earnings growth
99.49%
9.66%
Revenue (5-year growth)
-100%
6.43%
Earnings forecast
-$39.00
-$0.20
Profitability
WINT
Sector
Profitability FY 2024
-$84K
$2.3M
Return on invested capital
-320.18%
-33.49%
Return on assets
-150.5%
-29.74%
Return on equity
-760.4%
-39.33%
Earnings Date
Last Earnings Date
Aug
14
Next Earnings Date
Feb
27
Estimated Next Earnings Date
May
29
Balance Sheet
WINT
Sector
Total cash
$204K
$24.2M
Short term investments
--
$23.8M
Total assets
$27.9M
$71.1M
Long term debt
$240K
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
